Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Esketamine is not a breakthrough new drug: Why the nasal spray for depression is old news

Erik Messamore, MD, PhD
Meds
March 6, 2019
Share
Tweet
Share

The FDA has given official approval to market eskatamine as a treatment for depression. As expected, there has been great fanfare (press releases, morning TV talk show guests, NPR segments and so on). The news leaves me salty. The esketamine story reveals so much of what is wrong about how we get useful medical science findings into clinical practice.

Esketamine is not a new drug

Esketamine is being promoted as a new drug, as a breakthrough new drug. It’s not.

Drugs are complex molecules and complex molecules can have both right-handed and left-handed forms. Same chemical formula – just mirror-image forms. That’s how nature rolls.

Esketamine is the left-handed subtype of the very old, very cheap, and very generically-available drug ketamine.

It’s not a new drug. It’s just the left half of what the old drug used to be.

Using ketamine or esketamine to treat depression is not a breakthrough discovery

This part that chafes me the most. We’ve known since at least 2006 that ketamine (old, cheap, generic ketamine) rapidly shrink depressive symptoms. The antidepressant response occurs in a matter of hours and can last for up to a week after a single dose.

This fact has been in the medical literature for about 13 years.

There is a 10 percent suicide rate in severe depression. And about half of patients with depression don’t respond to first-line treatments.

There was an urgent (literally life-or-death) need to move generic ketamine into clinical practice. For 13 years, we could have been offering this treatment at scale, saving lives in the process.

The fact that we couldn’t do this speaks volumes.

We didn’t need eskatamine, really

We just needed a way to get 2006 medical science discoveries into clinical practice in less than 13 years.

ADVERTISEMENT

Why most patients couldn’t get ketamine for depression

I actually wanted to offer ketamine to my severely depressed and not-medication-responding patients. So, I called my professional liability insurance carrier. They told me: No way.

Absent FDA approval, they said, they would not stand by me if something bad happened.

Even if I were to take the risk of practicing without liability insurance, my patients’ insurance would not pay for it. Patients would have to pay out of pocket.

Also, most doctors were not aware of the ketamine story for many years. The ketamine data were published in the kinds of journals that most doctors don’t read.

Professional organizations like the American Psychiatric Association could have disseminated the ketamine story. They could even have lobbied to get insurance companies to cover the treatment and indemnify the clinicians. But nothing happened.

The easy work of developing eskatamine

Even though eskatamine is really just the left-handed half of ordinary ketamine, U.S. patent law allows for eskatmine to be patented.

With patent protection, Janssen Pharmaceuticals could then run the clinical trials necessary to get FDA approval.

From the company’s point of view, this was a triple win. First, they didn’t have to invent a drug. Ketamine was already there. Second, they didn’t have to spend a bunch of money on effectiveness discovery. We already knew that ketamine works and esketamine is really just ketamine. Finally, because of this, success in clinical trials was guaranteed.

So now, Janssen can sell a drug that’s very cheap to manufacture for about $800 per dose.

As a business move, this is brilliant.

As a story about how to quickly move treatments from science to the clinic, it reveals a problem.

Why did it take esketamine to get people to take seriously the use of ketamine for depression?

This is how medicine works in the modern era.

  • Without FDA approval, insurance companies will find a convenient excuse not to cover treatments – even if medical science shows that the treatment is useful.
  • Only pharmaceutical companies have enough money to get the FDA to look at data and opine on effectiveness.
  • Pharmaceutical companies won’t spend a dime to ask the FDA to review generic drugs like ketamine (or natural products like fish oil)
  • We do not have organizations are reliably willing to review non-industry-sponsored science and make recommendations about when a generic drug or natural product should move into clinical practice.

I find this situation tragic because the medical literature is jam-packed with discoveries that can solve clinical problems (often at low cost). Yet it’s a steep uphill battle to get this knowledge into clinical practice.

We sorely need to set up commissions that can review existing data and make FDA-like recommendations about on off-label use of generic drugs and natural products. You would be surprised how many diseases could be better treated if we were to create this kind of process. It shouldn’t take 13 years to get the next treatment from the clinical science journal into clinical service.

Erik Messamore is a psychiatrist and can be reached on Twitter @ErikMessamoreMD and LinkedIn.

Image credit: Shutterstock.com

Prev

After Luke Perry: a greater awareness of stroke symptoms

March 6, 2019 Kevin 1
…
Next

How telemedicine can help patients and solve physician burnout

March 6, 2019 Kevin 2
…

Tagged as: Medications, Psychiatry

Post navigation

< Previous Post
After Luke Perry: a greater awareness of stroke symptoms
Next Post >
How telemedicine can help patients and solve physician burnout

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

More by Erik Messamore, MD, PhD

  • Many medical marijuana program websites are silent about possible risks

    Erik Messamore, MD, PhD
  • It’s time to pay people to self-quarantine

    Erik Messamore, MD, PhD
  • America has seen medical marijuana before: This is what we learned (and forgot)

    Erik Messamore, MD, PhD

Related Posts

  • Are negative news cycles and social media injurious to our health?

    Rabia Jalal, MD
  • Treating depression with ketamine: We need incremental treatment for depression

    Shaili Jain, MD
  • How hospitals can impact generic drug companies

    Mark Kelley, MD
  • A drug problem in rural Georgia

    Ashish Advani, PharmD
  • Drug ads are a campaign against physician trust

    Judy Salz, MD
  • Crippling drug costs: the role of insurers

    Janice Boughton, MD

More in Meds

  • Why retail pharmacies are the future of diverse clinical trials

    Shelli Pavone
  • Why does rifaximin cost 95 percent more in the U.S. than in Asia?

    Jai Kumar, MD, Brian Nohomovich, DO, PhD and Leonid Shamban, DO
  • A world without antidepressants: What could possibly go wrong?

    Tomi Mitchell, MD
  • The truth about GLP-1 medications for weight loss: What every patient should know

    Nisha Kuruvadi, DO
  • The hidden bias in how we treat chronic pain

    Richard A. Lawhern, PhD
  • Biologics are not small molecules: the case for pre-allergy testing in an era of immune-based therapies

    Robert Trent
  • Most Popular

  • Past Week

    • Why removing fluoride from water is a public health disaster

      Steven J. Katz, DDS | Conditions
    • When did we start treating our lives like trauma?

      Maureen Gibbons, MD | Physician
    • Why male fertility needs to be part of every health conversation

      Hoag Memorial Hospital Presbyterian | Conditions
    • How home-based AI can reduce health inequities in underserved communities [PODCAST]

      The Podcast by KevinMD | Podcast
    • Inside human trafficking: a guide to recognizing and preventing it [PODCAST]

      The Podcast by KevinMD | Podcast
    • Graduating from medical school without family: a story of strength and survival

      Anonymous | Education
  • Past 6 Months

    • Why tracking cognitive load could save doctors and patients

      Hiba Fatima Hamid | Education
    • What the world must learn from the life and death of Hind Rajab

      Saba Qaiser, RN | Conditions
    • The silent toll of ICE raids on U.S. patient care

      Carlin Lockwood | Policy
    • My journey from misdiagnosis to living fully with APBD

      Jeff Cooper | Conditions
    • Addressing the physician shortage: How AI can help, not replace

      Amelia Mercado | Tech
    • Why does rifaximin cost 95 percent more in the U.S. than in Asia?

      Jai Kumar, MD, Brian Nohomovich, DO, PhD and Leonid Shamban, DO | Meds
  • Recent Posts

    • How home-based AI can reduce health inequities in underserved communities [PODCAST]

      The Podcast by KevinMD | Podcast
    • Adriana Smith’s story: a medical tragedy under heartbeat laws

      Nicole M. King, MD | Physician
    • What if medicine had an exit interview?

      Lynn McComas, DNP, ANP-C | Conditions
    • Why U.S. health care pricing is so confusing—and how to fix it

      Ashish Mandavia, MD | Physician
    • From survival to sovereignty: What 35 years in the ER taught me about identity, mortality, and redemption

      Kenneth Ro, MD | Physician
    • When doctors forget how to examine: the danger of lost clinical skills

      Mike Stillman, MD | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 2 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Why removing fluoride from water is a public health disaster

      Steven J. Katz, DDS | Conditions
    • When did we start treating our lives like trauma?

      Maureen Gibbons, MD | Physician
    • Why male fertility needs to be part of every health conversation

      Hoag Memorial Hospital Presbyterian | Conditions
    • How home-based AI can reduce health inequities in underserved communities [PODCAST]

      The Podcast by KevinMD | Podcast
    • Inside human trafficking: a guide to recognizing and preventing it [PODCAST]

      The Podcast by KevinMD | Podcast
    • Graduating from medical school without family: a story of strength and survival

      Anonymous | Education
  • Past 6 Months

    • Why tracking cognitive load could save doctors and patients

      Hiba Fatima Hamid | Education
    • What the world must learn from the life and death of Hind Rajab

      Saba Qaiser, RN | Conditions
    • The silent toll of ICE raids on U.S. patient care

      Carlin Lockwood | Policy
    • My journey from misdiagnosis to living fully with APBD

      Jeff Cooper | Conditions
    • Addressing the physician shortage: How AI can help, not replace

      Amelia Mercado | Tech
    • Why does rifaximin cost 95 percent more in the U.S. than in Asia?

      Jai Kumar, MD, Brian Nohomovich, DO, PhD and Leonid Shamban, DO | Meds
  • Recent Posts

    • How home-based AI can reduce health inequities in underserved communities [PODCAST]

      The Podcast by KevinMD | Podcast
    • Adriana Smith’s story: a medical tragedy under heartbeat laws

      Nicole M. King, MD | Physician
    • What if medicine had an exit interview?

      Lynn McComas, DNP, ANP-C | Conditions
    • Why U.S. health care pricing is so confusing—and how to fix it

      Ashish Mandavia, MD | Physician
    • From survival to sovereignty: What 35 years in the ER taught me about identity, mortality, and redemption

      Kenneth Ro, MD | Physician
    • When doctors forget how to examine: the danger of lost clinical skills

      Mike Stillman, MD | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Esketamine is not a breakthrough new drug: Why the nasal spray for depression is old news
2 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...